169 related articles for article (PubMed ID: 37364223)
1. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Colombo N; Van Gorp T; Matulonis UA; Oaknin A; Grisham RN; Fleming GF; Olawaiye AB; Nguyen DD; Greenstein AE; Custodio JM; Pashova HI; Tudor IC; Lorusso D
J Clin Oncol; 2023 Oct; 41(30):4779-4789. PubMed ID: 37364223
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.
Sridhar SS; Blais N; Tran B; Reaume MN; North SA; Stockler MR; Chi KN; Fleshner NE; Liu G; Robinson JW; Mukherjee SD; Rahim Y; Winquist E; Booth CM; Nguyen NT; Beardsley EK; Alimohamed NS; McDonald GT; Ding K; Parulekar WR
JAMA Oncol; 2020 Nov; 6(11):1751-1758. PubMed ID: 32940628
[TBL] [Abstract][Full Text] [Related]
3. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
[TBL] [Abstract][Full Text] [Related]
5. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
de la Rosa CN; Krell J; Day E; Clarke A; Reddi M; Webber L; Fiorentino F
Trials; 2022 Jan; 23(1):13. PubMed ID: 34986897
[TBL] [Abstract][Full Text] [Related]
6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
Giannatempo P; Raggi D; Marandino L; Bandini M; Farè E; Calareso G; Colecchia M; Gallina A; Ross JS; Alessi A; Briganti A; Montorsi F; Madison R; Necchi A
Ann Oncol; 2020 Dec; 31(12):1764-1772. PubMed ID: 32979512
[TBL] [Abstract][Full Text] [Related]
8. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Arend RC; Monk BJ; Shapira-Frommer R; Haggerty AF; Alvarez EA; Amit A; Alvarez Secord A; Muller C; Casado Herraez A; Herzog TJ; Tewari KS; Cohen JG; Huang M; Yachnin A; Holeman LL; Ledermann JA; Rachmilewitz Minei T; Buyse M; Fain Shmueli S; Lavi M; Harats D; Penson RT;
J Clin Oncol; 2024 Jan; 42(2):170-179. PubMed ID: 37906726
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
10. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Munster PN; Greenstein AE; Fleming GF; Borazanci E; Sharma MR; Custodio JM; Tudor IC; Pashova HI; Shepherd SP; Grauer A; Sachdev JC
Clin Cancer Res; 2022 Aug; 28(15):3214-3224. PubMed ID: 35583817
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant
Tempero MA; Pelzer U; O'Reilly EM; Winter J; Oh DY; Li CP; Tortora G; Chang HM; Lopez CD; Bekaii-Saab T; Ko AH; Santoro A; Park JO; Noel MS; Frassineti GL; Shan YS; Dean A; Riess H; Van Cutsem E; Berlin J; Philip P; Moore M; Goldstein D; Tabernero J; Li M; Ferrara S; Le Bruchec Y; Zhang G; Lu B; Biankin AV; Reni M;
J Clin Oncol; 2023 Apr; 41(11):2007-2019. PubMed ID: 36521097
[TBL] [Abstract][Full Text] [Related]
14. The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives.
Yang X; Fu C
Arch Gynecol Obstet; 2022 Nov; 306(5):1417-1429. PubMed ID: 35165749
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
17. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Pfisterer J; Joly F; Kristensen G; Rau J; Mahner S; Pautier P; El-Balat A; Kurtz JE; Canzler U; Sehouli J; Heubner ML; Hartkopf AD; Baumann K; Hasenburg A; Hanker LC; Belau A; Schmalfeldt B; Denschlag D; Park-Simon TW; Selle F; Jackisch C; Burges A; Lück HJ; Emons G; Meier W; Gropp-Meier M; Schröder W; de Gregorio N; Hilpert F; Harter P
J Clin Oncol; 2023 Feb; 41(4):893-902. PubMed ID: 36332161
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Colombo N; Tomao F; Benedetti Panici P; Nicoletto MO; Tognon G; Bologna A; Lissoni AA; DeCensi A; Lapresa M; Mancari R; Palaia I; Tasca G; Tettamanzi F; Alvisi MF; Rulli E; Poli D; Carlucci L; Torri V; Fossati R; Biagioli E;
Gynecol Oncol; 2022 Mar; 164(3):505-513. PubMed ID: 35063281
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Tempero M; Oh DY; Tabernero J; Reni M; Van Cutsem E; Hendifar A; Waldschmidt DT; Starling N; Bachet JB; Chang HM; Maurel J; Garcia-Carbonero R; Lonardi S; Coussens LM; Fong L; Tsao LC; Cole G; James D; Macarulla T
Ann Oncol; 2021 May; 32(5):600-608. PubMed ID: 33539945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
